Stockscreener 앱 받기
119.72
2.20%
-2.69
시장 영업 전:
120.00
0.28
+0.23%
전일 마감가:
$122.41
열려 있는:
$122.9
하루 거래량:
9.97M
Relative Volume:
1.04
시가총액:
$295.69B
수익:
$65.51B
순이익/손실:
$8.93B
주가수익비율:
33.69
EPS:
3.5532
순현금흐름:
$14.12B
1주 성능:
+4.80%
1개월 성능:
+6.99%
6개월 성능:
+14.42%
1년 성능:
+54.32%
1일 변동 폭
$119.41
$123.13
1주일 범위
$112.09
$123.13
52주 변동 폭
$75.40
$125.14
머크앤드컴퍼니 Stock (MRK) Company Profile
명칭
Merck Co Inc
전화
908-740-4000
주소
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK vs LLY, JNJ, ABBV, AZN
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
119.72 | 302.33B | 65.51B | 8.93B | 14.12B | 3.5532 |
LLY
Lilly Eli Co
|
1,064.74 | 949.70B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
230.18 | 564.11B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
213.12 | 381.10B | 62.82B | 3.60B | 19.98B | 2.0274 |
AZN
Astrazeneca Plc
|
187.19 | 290.06B | 60.48B | 10.40B | 8.05B | 3.3297 |
머크앤드컴퍼니 Stock (MRK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-25 | 개시 | RBC Capital Mkts | Outperform |
| 2026-02-20 | 개시 | Barclays | Overweight |
| 2026-02-13 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2026-01-08 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-12-18 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2025-11-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-10-13 | 재개 | Citigroup | Neutral |
| 2025-09-17 | 다운그레이드 | Berenberg | Buy → Hold |
| 2025-05-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2025-02-18 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-02-10 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-01-08 | 다운그레이드 | Truist | Buy → Hold |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-12-04 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-11 | 다운그레이드 | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-03-11 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2024-01-04 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Buy |
| 2023-10-27 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Hold |
| 2023-04-13 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-03-28 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2023-03-13 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | 개시 | Jefferies | Buy |
| 2023-02-22 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-10-10 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-09-14 | 업그레이드 | Berenberg | Hold → Buy |
| 2022-07-06 | 업그레이드 | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | 재개 | SVB Leerink | Outperform |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-12-17 | 개시 | Goldman | Buy |
| 2021-12-16 | 개시 | Daiwa Securities | Neutral |
| 2021-12-13 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-12-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-11-29 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-11-01 | 업그레이드 | Argus | Hold → Buy |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-05-20 | 다운그레이드 | Argus | Buy → Hold |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-08-03 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-06-12 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-08-16 | 개시 | SVB Leerink | Outperform |
| 2019-07-03 | 개시 | Mizuho | Buy |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-05-13 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | 재확인 | Citigroup | Buy |
| 2018-10-09 | 재개 | Guggenheim | Buy |
| 2018-04-23 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-04-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2018-03-12 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | 재확인 | Leerink Partners | Mkt Perform |
| 2018-02-07 | 재확인 | Morgan Stanley | Equal-Weight |
| 2018-01-16 | 업그레이드 | SunTrust | Hold → Buy |
모두보기
머크앤드컴퍼니 주식(MRK)의 최신 뉴스
Key facts: Merck posts growth; $0.85 Q3 dividend; supplies Keytruda - TradingView
Merck chicken bronchitis vaccine approved for use in China - Reuters
Merck Announces Third-Quarter 2026 Dividend - BioSpace
Merck & Co. Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Merck Co Inc declares Q3 2026 dividend of $0.85 per share - marketscreener.com
Merck Co Inc Declares Q3 2026 Dividend Of $0.85 Per Share - TradingView
Merck & Co. Inc. stock (US58933Y1055): Key cancer drug momentum after latest Keytruda and Lynparza u - AD HOC NEWS
Merck & Co., Inc. stock (US58933Y1055): 6 billion USD bond deal shifts focus to financing strategy - AD HOC NEWS
3 Dividend Stocks to Hold for the Next 10 Years - The Motley Fool
Merck & Co., Inc. (MRK) Completes $6 Billion Public Offering of Notes - GuruFocus
Legal & General Group Plc Has $2.08 Billion Stock Position in Merck & Co., Inc. $MRK - MarketBeat
Morningstar Investment Management LLC Sells 93,011 Shares of Merck & Co., Inc. $MRK - MarketBeat
RHL Group LLC Makes New Investment in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Holdings Decreased by New Age Alpha Advisors LLC - MarketBeat
Choate Investment Advisors Buys 13,581 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Bought by Fisher Asset Management LLC - MarketBeat
Merck & Co., Inc. stock (US58933Y1055): Key takeaways from the latest Keytruda and pipeline updates - AD HOC NEWS
Genus Capital Management Inc. Takes Position in Merck & Co., Inc. $MRK - MarketBeat
Mondrian Investment Partners LTD Sells 38,085 Shares of Merck & Co., Inc. $MRK - MarketBeat
Smead Capital Management Inc. Sells 196,374 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co Inc (MRK) Stock Price, Trades & News - GuruFocus
Catalyst Funds Management Pty Ltd Buys 22,100 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co. Inc. stock (US58933Y1055): FDA nod for Winrevair reshapes growth story - AD HOC NEWS
Merck & Co., Inc. stock (US58933Y1055): cancer franchise drives outlook after latest Keytruda data - AD HOC NEWS
Merck (MRK) Phase 3 TroFuse-005 Trial for Endometrial Cancer Meets Primary Endpoints - Yahoo Finance
LSV Asset Management Cuts Stake in Merck & Co., Inc. $MRK - MarketBeat
Legato Capital Management LLC Buys 8,759 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. stock (US58933Y1055): oncology momentum and fresh debt deal move MRK - AD HOC NEWS
A Look at Merck & Co Inc (MRK) After 5.6% Gain -- GF Value $118. - GuruFocus
A Look at Merck & Co Inc (MRK) After 5.6% Gain -- GF Value $118.14 vs Price $122.41 - GuruFocus
Research Alert: CFRA Raises Opinion On Shares Of Merck & Co., Inc. To Strong Buy From Buy - Moomoo
US58933YCE3 Bond Price and Chart — FWB:US58933YCE3 - TradingView
AbbVie, Merck, Astra among winners of EU drug recommendations this week - Seeking Alpha
Merck & Co Inc Stock (MRK) Opened Up by 4.50% on May 22: Facts Behind the Movement - TradingKey
Merck & Co., Inc. stock (US58933Y1055): Key cancer drug data and dividend profile in focus - AD HOC NEWS
Merck and Kelun's lung cancer combo bests Keytruda in late-stage trial - Seeking Alpha
Keudell Morrison Wealth Management Invests $1.33 Million in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Bought by Pinnbrook Capital Management LP - MarketBeat
Axxcess Wealth Management LLC Buys 263,633 Shares of Merck & Co., Inc. $MRK - MarketBeat
MRK News | MERCK & CO. INC. (NYSE:MRK) - ChartMill
MRK Stock Quote Price and Forecast - CNN
Merck and Ecolab lead M&A funding charge - GlobalCapital
Moderna, Merck cancer combo cuts melanoma spread risk at five years - Reuters
All Merck Articles - 24/7 Wall St.
Merck & Co., Inc. Balance Sheet – BVL:MRKUS - TradingView
44 WEALTH MANAGEMENT LLC's Merck & Co Inc(MRK) Holding History - GuruFocus
Merck & Co. Inc. stock (US58933Y1055): Keytruda data and Q1 2026 results keep pharma heavyweight in - AD HOC NEWS
Merck & Co. Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Merck & Co. Inc. stock (US58933Y1055): Key takeaways from the latest Keytruda growth and pipeline up - AD HOC NEWS
Merck & Co., Inc. stock (US58933Y1055): Key takeaways after latest Keytruda data and Q1 earnings - AD HOC NEWS
MRK6400123 Bond Price and Chart — FINRA:MRK6400123 - TradingView
머크앤드컴퍼니 (MRK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.09%
0.80%
자본화:
|
볼륨(24시간):